Loading
companiesCompany
Precigen
Precigen is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the adenoviral immunotherapies PRGN-2012 (Papzimeos) and PRGN-2009 in rare cancers of childhood and cervical cancer.
Also called: Intrexon
Overview
Precigen is a commercial-stage biopharmaceutical company developing precision medicines for difficult-to-treat diseases. Its first approved product, Papzimeos (zopapogene imadenovec, formerly PRGN-2012), is an adenoviral immunotherapy for recurrent respiratory papillomatosis; PRGN-2009 for HPV-associated cancers and the UltraCAR-T programmes are in phase 1. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT04724980 (phase 1/2, Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis) and NCT06157151 (phase 2, PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Ce...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Germantown, Maryland, US
Scorecard
All companies#72of 1244 companies, score 61
- approved products +6
- targets +2
- modalities +2
- regions +7
- 24-month regulatory events +14
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 2,094 registry studies. Formula on the scorecards page.
Type
Biotech · NASDAQ:PGEN
Stage
Public
Website
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
Similar pages
- CancerNasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)
Shares Rare cancers of childhood (NCI PDQ umbrella), Pembrolizumab.
- CancerRecurrent or metastatic cervical cancer
Shares PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer, Cervical cancer, Pembrolizumab.
cancers
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Pembrolizumab · Keytruda / Keytruda Qlex (SC)